Wadau, inaelekea kuna maendeleo katika harakati ya kutafuta chanjo dhidi ya UKIMWI:
************************************************************
TUSTIN, Calif., April 5 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq:PPHM - News) today announced the publication of data showing phosphatidylserine (PS)-targeting antibodies can block one of the key ways the AIDS virus gains entry into certain blood cells. The data were generated by scientists at Duke University as part of their ongoing AIDS vaccine research. The article titled "Anti-Phospholipid Human Monoclonal Antibodies Inhibit CCR5-Tropic HIV-1 and Induces Beta-Chemokines" is available online today and will be published in the April 12, 2010 edition of the Journal of Experimental Medicine. Peregrine's PS-targeting antibodies are currently in clinical development for the treatment of cancer and HCV infections.
Mnaweza kusoma Article nzima Hapa:
http://finance.yahoo.com/news/Peregrine-Pharmaceuticals-prnews-595526903.html?x=0&.v=1&.pf=banking-budgeting&mod=pf-banking-budgeting
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment